FDA Approves an Oncology Drug That Targets a Key Genetic Driver of Cancer

13:00 EST 27 Nov 2018 | Pharmaceutical Processing

News

Loxo Oncology's new drug Vitrakvi targets specific receptor kinase that promotes tumors.

Contributed Author:

The U.S. Food & Drug Administration

Topics:

More From BioPortfolio on "FDA Approves an Oncology Drug That Targets a Key Genetic Driver of Cancer"